Form4insider filings, from the source

SEC Form 4 · accession 0001209191-15-021473

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Feb 27, 2015
Accepted (ET)
Mar 3, 2015 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common stockF1Feb 27, 2015M25,000$0.3025A248,272ISee footnote
Common stockF3,F1Mar 2, 2015S6,500$107.05D241,772ISee footnote
Common stockF3,F4Mar 2, 2015S1,300$107.05D105,101ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock option (right to buy)F5$0.3025Feb 27, 2015M25,000D—Aug 12, 2019Common stock25,000753,320D
Stock option (right to buy)F6$107.89Mar 2, 2015A136,000A—Mar 1, 2025Common stock136,000889,320D

Explanation of responses